tiprankstipranks
Summit Therapeutics PLC (SMMT)
NASDAQ:SMMT
US Market
SMMT
Summit Therapeutics
RESEARCH TOOLSreports

Summit Therapeutics (SMMT) Income Statement

1,873 Followers

Summit Therapeutics Income Statement

Last quarter (Q4 2025), Summit Therapeutics's total revenue was £0.00, a decrease of ― from the same quarter last year. In Q4, Summit Therapeutics's net income was £-219.17M. See Summit Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
£ 0.00£ 0.00£ 0.00£ 704.29K£ 1.81M
Gross Profit
£ -108.36K£ -15.01M£ -2.05M£ -1.81M£ 1.81M
Operating Expenses
£ 1.09B£ 226.00M£ 87.69M£ 77.49M£ 88.00M
Depreciation and Amortization
£ 108.36K£ 17.15M£ 155.32K£ 1.26M£ 2.46M
EBITDA
£ -801.12M£ -212.85M£ -69.45M£ -73.12M£ -85.91M
Operating Income
£ -1.09B£ -211.30M£ -89.74M£ -79.30M£ -86.19M
Other Income/Expenses
£ 14.84M£ 4.70M£ -526.14M£ -4.00M£ -2.42M
Pretax Income
£ -1.08B£ -221.31M£ -615.87M£ -83.31M£ -88.60M
Net Income
£ -1.08B£ -221.31M£ -614.93M£ -78.78M£ -88.60M
Per Share Metrics
Basic EPS
£ -1.44£ -0.31£ -0.99£ -0.41£ -0.96
Diluted EPS
£ -1.44£ -0.31£ -0.99£ -0.41£ -0.96
Weighted Average Shares Outstanding
 747.70M 718.54M 619.65M 193.34M 92.24M
Weighted Average Shares Outstanding (Diluted)
 747.70M 718.54M 619.65M 193.34M 92.24M
Currency in GBP

Summit Therapeutics Earnings and Revenue History